Actinogen Medical Limited
ATGGF
Other OTC0.00
USD
- -
- -
Actinogen Medical Limited
ATGGF
(Other OTC)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Actinogen Medical Limited (ASX:ACW; OTC:ATGGF) develops novel oral therapies targeting dysregulated brain cortisol for neurological diseases, with its lead product Xanamem (emestedastat), a selective brain-penetrant inhibitor of the 11β-HSD1 enzyme that reduces cortisol synthesis in brain tissue while sparing adrenal function; the company advances Xanamem through late-stage clinical programs primarily in mild-to-moderate Alzheimer's disease and cognitive impairment associated with major depressive disorder (MDD), alongside earlier-stage efforts in Fragile X syndrome and potential expansions into bipolar disorder, PTSD, Lewy-body dementia, and frontotemporal dementia. Core pipeline activities center on the ongoing XanaMIA Phase 2b/3 trial in 220 biomarker-positive (elevated plasma pTau181) Alzheimer's patients assessing 10mg daily Xanamem versus placebo on the primary endpoint of Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) at 36 weeks, supported by secondary cognitive test battery and functional measures; completed Phase 2a XanaCIDD trial in 167 MDD patients demonstrated statistically significant improvements in depressive symptoms (MADRS scale, p<0.05 post-treatment) and patient-reported severity (PGI-S); prior Phase 2a XanADu in Alzheimer's showed slowed progression in high pTau181 subgroups (Cohen's d=0.4); and multiple Phase 1/2 trials (XanaHES, XanaMIA-DR, SAD/MAD) confirmed full brain target engagement via PET imaging, rapid cognitive benefits, excellent safety (over 400 subjects dosed, no serious drug-related adverse events), low drug interactions, and suitability for combination therapy. Founded in 2014 through a merger of University of Edinburgh spinout Corticrine with an ASX-listed shell and headquartered at Level 9, 109 Pitt Street, Sydney, Australia, Actinogen conducts multinational operations across Australia, the US (20 XanaMIA sites), and UK clinical centers, with manufacturing scaled at Catalent (US) and Asymchem (China); the company targets broad patient populations underserved by anti-amyloid antibodies, emphasizing oral convenience without invasive monitoring. Recent developments include positive Data Monitoring Committee recommendation in October 2025 to continue XanaMIA unamended with brisk enrollment (over 100 participants by mid-2025, full by Q4 2025, interim futility analysis January 2026, topline Q4 2026); FDA Type C meeting confirmation in September 2025 of streamlined US approval pathway via one additional pivotal trial, open-label safety, and minimal nonclinical work; A$11.1 million capital raise in September 2024 (A$8.1 million placement plus A$3 million SPP) extending runway to mid-2026; peer-reviewed publications on pTau181 progression and PET occupancy; and corporate presentations at key conferences including CTAD 2025, AAIC, and Bell Potter Healthcare. Strong intellectual property features composition-of-matter protection to 2036 (extendable), data exclusivity (5-10 years post-approval), and advanced patented tablet formulation; key shareholders include CEO Dr. Steven Gourlay (~5%) and institutional investors, positioning Actinogen for non-dilutive partnerships ahead of pivotal readouts.